PMID- 34196131
OWN - NLM
STAT- MEDLINE
DCOM- 20220425
LR  - 20220531
IS  - 2573-8348 (Electronic)
IS  - 2573-8348 (Linking)
VI  - 5
IP  - 3
DP  - 2022 Mar
TI  - Analyzing the influence of IL18 in regulation of YAP1 in breast oncogenesis using 
      cBioportal.
PG  - e1484
LID - 10.1002/cnr2.1484 [doi]
LID - e1484
AB  - BACKGROUND: Yes-associated protein 1 (YAP1) is responsible for tumor growth, 
      progression and metastasis. The mechanisms controlling the generation and 
      relative ratio of the functional YAP1 and other co-factors are not 
      well-understood. Various literature reported that co-factors like cytokines 
      significantly influence signaling pathways to introduce epithelial immunity and 
      regeneration, which later helps increase cancer-related phenotypes. Among various 
      cytokines, IL-18 has emerged as a major player in inflammation and progression of 
      different types of cancers. Till now, much information has not been known about 
      the role of YAP1 in tumor aggressiveness and immune evasion in breast cancer with 
      respect to IL-18. AIM: We aimed to explore the effect of YAP1 in tumor 
      aggressiveness and immune evasion in breast invasive carcinoma and metastatic 
      breast cancer in the context of Interleukin-18 (IL-18) in silico. METHODS AND 
      RESULTS: We used publicly available data generated by The Cancer Genome Atlas 
      (TCGA) Research Network through cBioportal web platform. Kaplan-Meier method was 
      used to determine the overall survival and comparison between curves were made 
      using Log-Rank test. The p values were determined by Fisher's exact test with the 
      null hypothesis. Correlation plots were analyzed by comparison with gene copy 
      numbers from the GISTIC2.0, available through cBioportal. Our analyses suggest 
      that IL-18 influences YAP1 expression in breast oncogenesis via Interferon-gamma 
      (IFN-gamma) production. Patients having a higher expression of IL-18 possess a better 
      prognosis and higher YAP1 expression with lower IL18 drives to poor clinical 
      results in breast cancer. CONCLUSION: This can provide new approaches to better 
      understand the relation between YAP1 and IL-18 in breast cancer progression by 
      performing in vitro and in vivo studies. Also, IL-18 can be considered as a 
      potential target for tumor treatment in YAP1 overexpressed breast carcinoma.
CI  - (c) 2021 The Authors. Cancer Reports published by Wiley Periodicals LLC.
FAU - Rahman, Ayesha
AU  - Rahman A
AUID- ORCID: 0000-0001-7740-1337
AD  - Department of Biology, Indian Institute of Science Education and Research, Pune, 
      Maharashtra, India.
FAU - Shashidhara, Lingadahalli S
AU  - Shashidhara LS
AD  - Department of Biology, Indian Institute of Science Education and Research, Pune, 
      Maharashtra, India.
AD  - Department of Biology, Ashoka University, Sonipat, India.
LA  - eng
GR  - PDF/2017/001677/DST SERB-NPDF/
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210630
PL  - United States
TA  - Cancer Rep (Hoboken)
JT  - Cancer reports (Hoboken, N.J.)
JID - 101747728
RN  - 0 (IL18 protein, human)
RN  - 0 (Interleukin-18)
RN  - 0 (YAP-Signaling Proteins)
RN  - 0 (YAP1 protein, human)
SB  - IM
MH  - Breast/pathology
MH  - *Breast Neoplasms/pathology
MH  - Carcinogenesis/genetics
MH  - Cell Transformation, Neoplastic/genetics
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - *Interleukin-18/genetics/metabolism
MH  - *YAP-Signaling Proteins/genetics
PMC - PMC8955059
OTO - NOTNLM
OT  - IL18
OT  - YAP1
OT  - breast cancer
OT  - cBioPortal
COIS- The authors declare there is no conflict of interest.
EDAT- 2021/07/02 06:00
MHDA- 2022/04/26 06:00
PMCR- 2021/06/30
CRDT- 2021/07/01 07:32
PHST- 2021/05/04 00:00 [revised]
PHST- 2021/02/08 00:00 [received]
PHST- 2021/06/14 00:00 [accepted]
PHST- 2021/07/02 06:00 [pubmed]
PHST- 2022/04/26 06:00 [medline]
PHST- 2021/07/01 07:32 [entrez]
PHST- 2021/06/30 00:00 [pmc-release]
AID - CNR21484 [pii]
AID - 10.1002/cnr2.1484 [doi]
PST - ppublish
SO  - Cancer Rep (Hoboken). 2022 Mar;5(3):e1484. doi: 10.1002/cnr2.1484. Epub 2021 Jun 
      30.